trending Market Intelligence /marketintelligence/en/news-insights/trending/Ae1ISRFOtEDCHRkJ4JoMIQ2 content esgSubNav
In This List

Corporate Venture, Pluristem to advance limb treatment in Japan

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Corporate Venture, Pluristem to advance limb treatment in Japan

Pluristem Therapeutics Inc. is establishing a new joint venture company with Corporate Venture Capital Ltd. to develop and commercialize its PLX-PAD cell therapy in Japan.

The parties have signed a binding term sheet and expect to reach a definitive agreement by March 31, 2017, under which Corporate Venture's investment fund Sosei RMF1 will invest $11 million for a 65% stake.

Corporate Venture itself is part of the Sosei Group Corp.

PLX-PAD is currently being developed for the treatment of critical limb ischemia, a severe obstruction of arteries that leads to severe pain and skin ulcers or sores on hands, feet and legs.

The treatment has been approved for clinical trial in Japan.